Next Day Disclosure Return
Filed with HKEX · Stock code 2595 · · 6 pages · English
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- List of directors and their roles and functions
- Resignation of non-executive director
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
- Announcement pursuant to rule 13.10 of the listing rules
Later from Genfleet Therapeutics (Shanghai)
- VOLUNTARY ANNOUNCEMENT GFH375/VS-7375 (Oral KRAS G12D Inhibitor) Achieves Positive Progress across Multiple Clinical Studies in China and Abroad, with Promising Efficacy in Various RAS-mutant Solid Tumors
- VOLUNTARY ANNOUNCEMENT Initial Clinical Readout of GFH276 (an Oral Molecular-glue Pan RAS Inhibitor) Presented as Late-breaking Abstract (LBA) at 2026 ESMO Annual Meeting, Demonstrating Promising Clinical Potential and Favorable Safety in Pretreated RAS-mutant Solid Tumors
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)